Rule-Based Identification of a Reliable Real-World Cancer Recurrence Endpoint.
This scalable method enables derivation of real-world endpoints from EHR-based data and may be used to characterize outcomes for patients treated outside of prospective clinical trials and may inform the creation of synthetic control cohorts to support regulatory approvals for new drugs in rare tumor or biomarker defin...